Award Data

DESCRIPTION (provided by applicant): The broad long-term objectives of the proposed work are to develop effective medical countermeasures to be used for the treatment of viral infectious disease caused by exposure to human coronaviruses. The work will focus on the discovery and development of peptide-based therapeutics for the treatment of persons infected with the newly identified Middle Eastern ...

DESCRIPTION (provided by applicant): Calista Therapeutics has invented Calcaftor, a first-in-class peptide drug that can treat all Cystic Fibrosis (CF) patients. Calcaftor is validated in the gold standard pre-clinical model of CF using F508 -CFTR lung tissue harvested from CF transplant patients. Results from this model demonstrated a gt25 hour duration of action that enables once daily inhaled n ...

DESCRIPTION (provided by applicant): Neonatal hypoxia-ischemia (HI) remains a major cause of acute perinatal brain injury, leading ultimately to neurologic dysfunction manifesting as cerebral palsy, mental retardation, and epilepsy. Cerebral oxygen deprivation and/or reduced blood flow due to umbilical cord occlusion, prolonged labor, and/or intracranial hemorrhage produce an inflammatory respons ...

PROJECT SUMMARY Cardiovascular disease (CVD) remains the number one cause of death in the U.S. Left untreated, CVD can result in the occlusion of key arteries that can precipitate a major cardiac event. Clinicians routinely correct arterial blockages mechanically using a balloon expansion of the lesioned area and placement of a metallic stent to help keep the arteries open. However, the overstretc ...

The overarching objective of this project is to develop an innovative technological tool that will facilitate the implementation of an evidence-based substance abuse prevention program and related health behavior risk programs among military personnel. PUBLIC HEALTH RELEVANCE

DESCRIPTION: We have preliminary data for a small molecule glyco-decoy that specifically side-tracks the biosynthesis of the ligand for E-selection, and is a candidate for a novel anti-inflammatory. The three members E, L and P of the selection family areinflammatory adhesion molecules expressed constitutively on the surface of blood leukocytes and on activated endothelial cells and platelets. Dis ...

DESCRIPTION (provided by applicant): Calista Therapeutics has discovered a first-in-class, proprietary PDZ1-2 lead drug, AT010, that is being optimized and developed as an inhaled daily therapy for cystic fibrosis (CF). CF is a deadly inherited genetic disorder that disrupts chloride channel function, resulting in the buildup of sticky mucus in patient's lungs and other organs.CF patients hav ...

DESCRIPTION (provided by applicant): Chronic musculoskeletal pain creates a significant public health burden. Veterans are disproportionately affected by chronic musculoskeletal pain, and in particular, chronic low back pain (CLBP). The frequency and extent of co-occurrence of pain and PTSD, pain and Traumatic Brain Injury (TBI), and all three conditions (Post-deployment Multi-symptom Disorder (PM ...

DESCRIPTION (provided by applicant): The principal goal of this research project will be to evaluate 4-demethyl-4- cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN), a polychlorinated cholesterol carbonate as anticancer therapy for patients with advanced cancer in a Phase II clinical trial. During pre-clinical studies DM-CHOC-PEN produced complete remissions with long term survival vs. intracranial ...

DESCRIPTION (provided by applicant): Researchers and contractors are under increasing pressure to produce rapid turnaround times for data releases and publications. Inadequate data management is a common threat to good research and impedes the quick release of high value data. Despite its importance, many organizations do not have standardized data management practices that allow them to prepare h ...